https://www.selleckchem.com/pr....oducts/gsk2643943a.h
In HFD-induced diabetic mouse model, administration of Pri (100 μg· kg-1 ·d-1, ip, for 6 weeks) reversed HFD-induced metabolic disorders via suppression of NLRP3 inflammasome activation. Taken together, our results demonstrate that Pri acts as a NLRP3 inhibitor, suggesting that Pri might be useful for the treatment of NLRP3-associated diseases.The unprecedented COVID-19 pandemic of 2019-2020 generated an equally unprecedented response from government institutions to control contagion. These legal responses included shelter in place
Like
Comment
Share
